期刊
NPJ PRECISION ONCOLOGY
卷 2, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41698-018-0067-9
关键词
-
类别
资金
- NCI Cancer Center Support Grant [P30CA138292]
- National Brain Tumor Society (NBTS)
- loglio research project
- Oligo Nation
- U.S. Public Health Service through National Institutes of Health [R01CA176659, U24CA194362, K22LM011576]
- National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454, TL1TR000456]
- Winship Cancer Institute NCI Cancer Center Support Grant [P30CA138292]
- NATIONAL CANCER INSTITUTE [U24CA194362, R01CA176659, P30CA138292] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454, UL1TR002378, TL1TR000456] Funding Source: NIH RePORTER
- NATIONAL LIBRARY OF MEDICINE [K22LM011576] Funding Source: NIH RePORTER
Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据